LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

LENZ Therapeutics, Inc.NASDAQ: LENZ

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns positive

Q1 FY2026 gross profit was $714K, compared with -$36K a year earlier. Trailing-twelve-month gross profit was $19.13M. Over 3 fiscal years it compounded at +7.0% a year.

Context

  • Gross profit amounted to 96.3% of revenue in FY2025.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $714K or moves back toward the trailing-twelve-month quarterly average of $4.78M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$714K-32.8% QoQ
Last fiscal yearDec 2025
$18.38M+31794.8% YoY
LTMMar 2026
$19.13M+53247.2% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2083.3%——
1 year+31794.8%——
3-year CAGR+7.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
18.38M USD
Year-over-year change
+31794.8%

Gross Profit vs competitors

How LENZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +53247.2% is the highest of 9, against a peer median of +32.1%.
  • Gross profit amounts to 91.2% of revenue for LENZ, versus a peer median of 93.3%.
LENZ Competitors
Gross Profit for LENZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$191.41M USD+1784.1%-29.4%100.0%
GERNGeron CorporationLTM Mar 2026$169.81M USD+49.2%+569.9%86.6%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$76.32M USD-7.1%—77.1%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$72.25M USD+15.0%-64.0%34.6%
NBTXNanobiotix S.A.FY2025€29.64M EUR+512.3%+83.8%100.0%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$19.13M USD+53247.2%+7.0%91.2%
RZLTRezolute, Inc.LTM Mar 2026-$23K USD———
TYRATyra Biosciences, Inc.LTM Mar 2026-$138K USD-9.5%——
GHRSGH Research PLCLTM Mar 2026-$268K USD———
SVRASavara Inc.LTM Mar 2026-$491K USD+97.8%——
PRMEPrime Medicine, Inc.LTM Mar 2026-$43.68M USD-1235.6%—1082.7%
Peer median (excluding LENZ) —+32.1%+27.2%93.3%

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015M0019.09M
Cost of Revenue734K0058K705K
Gross Profit(734K)15M0(58K)18.38M
Gross Margin—100.0%——96.3%
Research & Development37.93M21.13M59.5M29.8M18.67M
Selling, General & Admin21.78M4.36M12.93M28.75M90.85M
Operating Expenses59.71M25.48M72.43M58.55M109.52M
Depreciation & Amortization734K8K15K58K287K
EBITDA(70.03M)(10.46M)(70.13M)(49.71M)(81.34M)
EBITDA Margin—-69.7%——-426.1%
Operating Income(60.44M)(10.48M)(72.43M)(58.61M)(91.14M)
Operating Margin—-69.9%——-477.5%
Interest Income002.19M8.55M9.76M
Interest Expense00000
Other Income / Expenses(10.32M)19K2.28M8.84M9.51M
Income Before Tax(70.76M)(10.46M)(70.15M)(49.77M)(81.63M)
Pre-Tax Margin—-69.8%——-427.6%
Income Tax Expense0347K(179K)1K502K
Net Income(70.76M)(10.81M)(69.97M)(49.77M)(82.13M)
Net Margin—-72.1%——-430.3%
EPS (Basic)(8.54)(12.89)(15.30)(2.34)(2.85)
EPS (Diluted)(8.54)(12.89)(15.30)(2.34)(2.85)
Weighted Avg Shares8.29M7.84M8.15M21.28M28.81M
Weighted Avg Shares (Diluted)8.29M7.84M8.15M21.28M28.81M

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.